Clearmind Medicine (CMND) stock price is flying but risks remain

November 30, 2023 07:22 AM PST | By Invezz

Google News:

Clearmind Medicine (CMND) stock price is flying but risks remain — Image source: Invezz

Recent News

Brink's Company Shows Upward Momentum Despite Earnings Lag NYSE Compos...

KeyCorp (NYSE:KEY) Cuts Stake by Financial Firm Amid Market Russell 10...

Royal Caribbean Cruises Ltd Shares Surge Amid Positive Growth Sentimen...

Primerica’s (NYSE:PRI) Strong ROE Signals Stable Growth Amid Steady Ea...

Clearmind Medicine (NASDAQ:CMND) stock price was among the best-performing in Wall Street on Thursday. The share jumped by more than 32% and reached a high of $5.37. Still, the penny stock remains in trouble after it crashed by over 94% in the last 12 months. It has plunged by over 98% from its all-time high.

The main reason why the CMND share price surged is that the company announced a positive results from its weight loss and metabolic disorder program. The Israeli company’s product combined the company’s proprietary MEAI, obesity and metabolic disorders and depression, and SciSparc’s Palmitoylethanolamide (PEA). In a statement, the company said:

“Over the past year, we have witnessed an increased demand of medication for weight loss, even though they exhibit severe side effects and have even lead to hospitalization. I believe that our proprietary drug candidate, MEAI, is a potentially better and safer option compared to other weight-loss drugs currently on the market.”

Clearmind Medicine is a biotech company aiming to disrupt the fast-growing industry of weight loss drugs that is being dominated by the likes of Eli Lilly and Novo Nordisk. These companies have come up with products like Ozempic, Wegovy, and Mounjaro. These drugs have become so popular, with Ozempic expected to make over $12.5 billion this year.

Therefore, most analysts believe that Clearmind Medicine faces a tough path ahead because of the strong barriers to entry. In addition to Eli Lilly and Novo Nordisk, other companies like Pfizer and AstraZeneca are developing competing products.

ClearMind is a relatively small company that is fighting for survival. It has a market cap of just $1.85 million and is struggling to support its NASDAQ listing. It recently made a share split that enabled its stock to remain above $1.

Clearmind Medicine has also diluted its shareholders in the past few months. Its outstanding shares have jumped from less than 50k in 2021 to over 237k today. Also, while its balance sheet has over $4 million in cash, it is also burning a lot of money every quarter. It had a net loss of over $0.6 million in the June quarter.

The post Clearmind Medicine (CMND) stock price is flying but risks remain appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.